DEMANT

The global hearing aid industry is one of the most structurally concentrated markets in healthcare. Roughly 95% of all hearing instruments sold worldwide originate from five companies: Demant, Sonova, WS Audiology (the Sivantos-Widex combination), GN Hearing (part of GN Store Nord), and Starkey. Within this oligopoly, Demant and Sonova occupy the top two positions, together controlling an estimated 45 to 50% of the global wholesale market and an even larger share of the retail audiology channel. Demant, headquartered in Smorum, Denmark, and founded in 1904, has spent over a century building a position that competitors cannot replicate quickly: it designs its own chipsets, manufactures its own hearing instruments under the Oticon, Bernafon, and Philips HearSuite brands, and operates thousands of hearing care clinics worldwide under names like Audika, HearingLife, and other regional banners.

The central analytical question for Demant in 2026 is not whether its structural position is durable. It is whether a company that has defined the rules of its industry for decades can sustain its power while simultaneously absorbing a major acquisition wave, divesting its underperforming communications business (EPOS), and navigating margin compression that cut reported EPS from DKK 11.10 in 2024 to just DKK 7.31 in 2025. The hearing aid market's structural tailwind remains intact: an aging global population, increasing awareness of hearing loss treatment, and regulatory shifts such as the U.S. introduction of over-the-counter (OTC) hearing aids are expanding the addressable market. But Demant's near-term financials tell a different story. Discontinued operations losses totaling DKK 823 million in FY2025, combined with DKK 6.24 billion in net acquisitions during the year, reveal a company in transition. The moat is real and deep. The question is whether the company is overextending itself at precisely the moment when disciplined capital allocation matters most.

Here is the L17X insight that standard financial providers miss: Demant does not merely sell hearing aids. It controls the audiological decision architecture. When an audiologist in a Demant-owned clinic fits a patient, the chipset, the fitting software, the calibration algorithm, and the aftercare relationship all belong to Demant. This vertical integration is not a business strategy supplement. It is the moat itself. And it compounds, because each clinic acquisition adds another node to a distribution network that competitors must either replicate at enormous capital cost or accept as a permanent structural disadvantage.